Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ...

Published 2024-05-23, 09:17 p/m
Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ...
MDGL
-

GuruFocus - On May 21, 2024, Robert Waltermire, Senior Vice President and Chief Pharmaceutical Development Officer at Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), sold 1,036 shares of the company. The transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 5,500 shares of Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is engaged in the development of novel therapies that address unmet needs in the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate, resmetirom, is in advanced clinical trials targeting non-alcoholic steatohepatitis (NASH).

Over the past year, Robert Waltermire has sold a total of 8,836 shares and has not made any purchases of the company's stock. This recent sale is part of a broader trend observed at Madrigal Pharmaceuticals Inc, where there have been 13 insider sells and 6 insider buys over the past year.

On the date of the transaction, shares of Madrigal Pharmaceuticals Inc were priced at $231.34, valuing the company with a market cap of approximately $5.01 billion. This valuation reflects the company's position in the market and its potential growth in the pharmaceutical sector.

For investors, understanding the trends in insider transactions can provide insights into the company's internal perspective on the stock's valuation and future prospects. For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors are encouraged to visit the respective links.

This insider sale event is a part of the ongoing financial activities at Madrigal Pharmaceuticals Inc, which stakeholders and potential investors may want to consider as they assess the company's stock and its future in the pharmaceutical industry.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This content was originally published on Gurufocus.com

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.